A prospective study of renal failure in multiple myeloma: A promising role for plasmapheresis

HAEMA

Volumn 6, Issue 3, 2003, Pages 358-365

  Abdulrahman, Ibrahiem Saeed ^a  

^a IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY   (Saudi Arabia)

Author keywords

Multiple myeloma; Plasmapheresis; Renal failure

Indexed keywords

CREATININE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN KAPPA CHAIN;

ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; FEMALE; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERURICEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; MULTIPLE MYELOMA; OLIGURIA; PLASMAPHERESIS; PNEUMONIA; PROGNOSIS; PROTEINURIA; SEPTICEMIA; SURVIVAL;

EID: 0141449119     PISSN: 11082682     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Kyle RA. Multiple myeloma: Review of 869 cases. Mayo Clinic Proc 1975; 50: 29-40.
2. Martinez-Maldonado M, Yium J, Suki WN et al. Renal complications in multiple myeloma. Pathophysiology and some aspects of clinical management. J Chronic Dis 1971; 24: 221-237
3. Alexanian R, Barlogie B, Dixon D. Renal failure in multiple myeloma: pathogenesis and prognostic implications. Arch Intern Med 1990; 150: 1693-1695.
4. Bernstein SP, Humes HD. Reversible renal insufficiency in multiple myeloma. Arch Intern Med 1982; 142: 2083-2086.
5. Rota S, Mougenot B, Baudouin, et al. Multiple myeloma and severe renal failure: a clinicopathologic study of outcome and prognosis in 34 patients. Medicine 1987; 66: 126-137.
6. Torra R, Blade J, Cases A et al. Patients with multiple myeloma requiring long term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 1995; 91: 854-859.
7. Pasqualis S, Casanova S, Zuchelli A. Long term survival in patients with acute and severe renal failure due to multiple myeloma. Clin Nephrol 1990; 34: 247-253.
8. Cohn DJ, Sherman WH, Osserman EF et al. Acute renal failure in patients with multiple myeloma. Am J Med 1984; 67: 247-256.
9. Maclennan ICM, Drayson M, Dunn J. Multiple myeloma. Br Med J 1994; 308: 1033-1036.
10. Kaplan GL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-548.
11. Cox DR. Analysis of Binary Data. Methuen and Co Ltd., London, 1970.
12. Cox DR. Regression models and life tables. J R Stat Soc. 1972; 34: 187-220.
13. Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc 1975; 50: 29-40.
14. Carbone PP, Kellerhouse LE, Gehan E. Plasmacytic myeloma: a study of the relationship of survivial to various clinical manifestations and anomalous protein type in 112 patients. Am J Med 1976; 42: 937-948.
15. Sakhuja V, Jha V, Varma S et al. Renal involvement in multiple myeloma: a 10-year study. Ren Fail 2000; 22: 465-477.
16. Herrera GA. Renal manifestations of plasma cell dyscrasias: an appraisal from the patient's bedside to the research laboratory. Ann Diagn Pathol 2000; 4: 174-200.
17. Rayner Hc, Haynes AP, Thompson JR et al. Prospectives, multiple myeloma: survival, prognostic factors and disease complications in a single center between 1975 and 1988. Q J Med 1991; 79: 517-525.
18. Winearls CG, Nephrology forum-Acute myeloma kidney. Kidney Int 1995; 48: 1347-1361.
19. Border WA, Cohen AH. Renal biopsy diagnosis of clinically silent multiple myeloma. Ann Intern Med 1980; 93: 43-46.
20. Gunda S, Kwan JT, Sampson S. Hypercalcemia and acute renal failure. Nephrol Dial Transplant 2001; 16: 425-426.
21. Pozzi C, Pasquali S, Donini U et al. Prognostic factors and effectiveness of treatment in acute renal failure due to multiple myeloma: a review of 50 cases. Report of the Italian Renal Immunopathology Group. Clin Nephrol 1987; 28: 1-9.
22. Magee C, Vella JP, Tormey WP et al. Multiple myeloma and renal failure: one center's experience. Ren Fail 1998; 20: 597-606.
23. Ueno M, Ohigashi T, Nakashima J et al. Hypercalcemia and acute renal failure caused by production of parathyroid hormone-related protein from renal cell carcinoma. Scan J Urol Nephrol 2002; 36: 149-151.
24. Farias ML, Delgado AG, Rosenthal D et al. Changes in renal hemodynamics and tubular function of surgically cured primary hyperparathyroid patients are probably due to chronic hypercalcemic nephropathy. J Bone Miner Res 1998; 13: 1679-1686.
25. Smolens P, Barnes JL, Kreisberg R. Hypercalcemia can potentiate the nephrotoxicity of Bence Jones Proteins. J Lab Clin Med 1987; 110: 460-465.
26. Clark AD, Shetty A, Soutar R. Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Rev 1999; 13: 79-90.
27. Wu MJ, Kumar KS, Kulkarni G et al. Multiple myeloma in Naproxen-induced acute renal failure (Letter). N Engl J Med 1987; 317: 170-71.
28. Shpilberg O, Douer D, Ehrenfled M et al. Naproxen-associated fatal acute renal failure in multiple myeloma (Letter). Nephron 1990; 55: 448-49.
29. Al Shohaib S. Injection of diclofenac precipitating oliguric acute renal failure in a patient with kidney myeloma. Nephron 2000; 85: 96-96.
30. Dubose TD, Molony DB, Verani R et al. Nephrotoxicity of non-steroidal anti-inflammatory drugs. Lancet 1994; 344: 515-518.
31. McCarthy CS, Becker JA. Multiple myeloma and contrast media. Radiology 1992; 183: 519-521.
32. Paradisi F, Corti G, Cinelli R. Infections in multiple myeloma. Infect Dis Clin North Am 2001; 15: 373-384, vii-viii.
33. Kurtsonis MC, Mouzaki A, Maniatis A. Mechanisms of polyclonal hypogammaglobulinemia in multiple myeloma (MM). Med Oncol 1999; 16: 73-77.
34. Zager RA. Endotoxemia, renal hypoperfusion and fever: Interactive risk factors for aminoglycoside and sepsis-associated acute renal failure. Am J Kidney Dis 1992; 20: 223-230.
35. Bernstein S, Humes H. Reversible renal insufficiency in multiple myeloma. Arch Intern Med 1982; 142: 2083-2086.
36. Kes P, Pecanic Z, Getaldic B. Plasmapheresis and hemodialysis in the treatment of acute renal failure in multiple myeloma. Acta Med Croatica 1995; 49: 39-42.
37. Sharland A, Snowdon L, Joshua DE et al. Hemodialysis: an appropriate therapy in myeloma-induced renal failure. Am J Kidney Dis 1997; 30: 786-792.
38. Sirohi B, Powles R, Mehta J et al. The implication of compromised renal function at presentation in myeloma: similar outcome in patients who receive high-dose therapy: a single center study of 251 previously untreated patients. Med Oncol 2001; 18: 39-50.
39. Johnson WJ, Kyle RA, Pineda AA et al. Treatment of renal failure associated with multiple myeloma: plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med 1990; 150: 863-869.
40. Misiani R, Tiraboschi G, Mingardi G et al. Management of myeloma kidney: an anti-light chain approach. Am J Kidney Dis 1987; 10: 28-33.
41. Blade J, Fernandez-Llama P, Bosch F et al. Renal Failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998; 158: 1889-1893.
42. Siami GA, Siami FS. Plasmapheresis and paraproteinemia: cryoprotein-induced disease, monoclonal gammopathy, Waldenstrom's macroglobulinemia, hypervescosity syndrome, multiple myeloma, light chain disease, and amyloidosis. Ther Apher 1999; 3: 8-19.
43. Viertel A, Weidmann E, Ditting T et al. Management of renal complications in patients with advanced multiple myeloma. Leuk Lymphoma 2000; 38: 513-519.
44. Wahlin A, Lofvenberg E, Holm J. Improved survival in multiple myeloma with renal failure. Acta Med Scand 1987; 221: 205-209.